Verrica Unlocks Full $27.5 Million Credit Facility to Support YCANTH Growth and Warts Trials

Key Points

• Verrica met revenue, growth and operational milestones that unlocked an additional $15 million in borrowing capacity.
• The full $27.5 million facility is now available, including $12.5 million already funded in September.
• The company says the financing will support YCANTH’s commercial growth and completion of two pivotal common-warts studies.
• Trial results are expected in the first quarter and around mid-2027.
• The funding avoids issuing new shares, but it is debt with a minimum annual interest rate of 12.5%.

Verrica Pharmaceuticals (NASDAQ: VRCA) has gained access to the full $27.5 million available under its credit facility after meeting predefined business milestones.

The announcement expands the company’s borrowing capacity; it does not mean another $27.5 million has been deposited. Verrica received the first $12.5 million in September and can now borrow the remaining $15 million at its option.

Funding Supports YCANTH Sales and Two Phase 3 Readouts

Verrica plans to use the financing to support its YCANTH business and advance two pivotal studies evaluating the treatment for common warts.

The company expects the first study’s results in the first quarter of 2027 and the second around midyear. Management says the available funding will allow it to complete both studies.

YCANTH is already FDA-approved for molluscum contagiosum in adults and children aged two and older. Common warts remain an investigational use.

Interest Adds to the Debt Balance Rather Than Requiring Regular Cash Payments

Borrowings carry interest at one-month SOFR plus 8%, with a SOFR floor of 4.5%. That creates a minimum annual rate of 12.5%.

Under normal conditions, interest is paid in kind—added to the debt balance rather than paid in cash. The loans mature on December 31, 2030.

Although the facility generally avoids scheduled cash principal and interest payments during its term, certain events can trigger payments. These include specified transactions, operating cash flow above a threshold and default-related provisions.

The debt is secured by substantially all assets of Verrica and certain subsidiaries.

Facility Comes From an Entity Controlled by Verrica’s Chairman

The lender is an entity controlled by Paul Manning, Verrica’s board chairman and the chairman and CEO of PBM Capital.

Manning said the company’s recent execution reinforced his confidence in its team and YCANTH. Verrica did not disclose the specific performance thresholds it met to unlock the additional funding.

Investor Takeaway: More Financial Flexibility, With a Growing Debt Obligation

For VRCA investors, the expanded facility provides access to capital without issuing additional shares and supports two upcoming clinical milestones.

However, “non-dilutive” does not mean cost-free. Interest will increase the amount owed, and the secured borrowing creates repayment obligations. The next key developments are YCANTH’s commercial performance and the common-warts trial results expected in 2027.